TITLE

Validated HPLC—MS—MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma–pharmacokinetic study

AUTHOR(S)
Bořek-Dohalský, V.; Huclová, J.; Barrett, B.; Němec, B.; Ulč, I.; Jelínek, I.
PUB. DATE
October 2006
SOURCE
Analytical & Bioanalytical Chemistry;Oct2006, Vol. 386 Issue 2, p275
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cholesterol-reducing statin drugs are the most frequently prescribed agents for reducing morbidity and mortality related to coronary heart disease. In this publication a validated, highly sensitive, and selective isocratic HPLC method is reported for quantitative determination of the major statin drug atorvastatin (ATV) and its metabolite 2-hydroxyatorvastatin (HATV). Detection was performed with an electrospray ionization triple-quadrupole mass spectrometer equipped with an ESI interface operating in positive-ionization mode. Multiple reaction monitoring (MRM) was used for MS–MS detection. The calibration plot was linear in the concentration range 0.10–40.00 ng mL−1 for both ATV and HATV. Inter-day and intra-day precision and accuracy of the proposed method were characterized by measurement of relative standard deviation (RSD) and percentage deviation, respectively; both were less than 8% for both analytes. The limit of quantitation was 0.02 ng mL−1 for ATV and 0.07 ng mL−1 for HATV. The method was used for pharmacokinetic study of ATV and HATV. Pharmacokinetic data for all analytes are also reported.
ACCESSION #
22164379

 

Related Articles

  • COMMENTARY: Review: Early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes. Carey, Brian C.; Berger, Peter B. // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p61 

    The article presents the author's comments on a study that was conducted to determine whether early statin therapy reduces the composite endpoint of death in patients with recent onset of the acute coronary syndrome. Despite agreeing with some of the findings of the study, the author believes...

  • The National Service Framework on coronary heart disease: is it sufficiently evidence-based? Ferns, Gordon A. A. // Annals of Clinical Biochemistry;May2001, Vol. 38 Issue 3, p159 

    The article presents the author's comments on the use of statins in the acute phase of myocardial infarction (MI). The British National Service Framework sets out 12 standards on the use of statins for reducing coronary morbidity and mortality. These standards recommend the use of statins in MI....

  • Review: Early statin therapy does not reduce the composite endpoint of death, MI, or stroke in acute coronary syndromes.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p61 

    The article presents information on a study that was conducted to determine whether early statin therapy reduces the composite endpoint of death in patients with recent onset of the acute coronary syndrome. The study compared the efficacy of statin therapy with that of placebo. It was concluded...

  • Early statins can halve post MI death risk. Kumar, Rajesh // New Zealand Doctor;9/21/2005, p5 

    Focuses on the ability of statin therapy to reduce the risk of mortality after a heart attack according to research published in the September 2005 issue of the "American Journal of Cardiology." Association of the use of statin with a lower incidence of cardiogenic shock, arrhythmias and...

  • Use of lipid-modulating drugs in complicated course of coronary heart disease. N. Gratsianskii; N. Vaulin // Bulletin of Experimental Biology & Medicine;Sep2007, Vol. 144 Issue 3, p438 

    Abstract  We present the results of the study of lipid-modulating drugs (pravastatin, atorvastatin, simvastatin, and fibrate gemfibrozil) in complicated coronary heart disease (acute coronary syndrome without ST elevation, chronic heart failure. In acute coronary syndrome statins produced...

  • 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering Agents. Gordon, David J.; Rifkind, Basil M. // Annals of Internal Medicine;Nov87, Vol. 107 Issue 5, p759 

    Editorial. Deals with the approval given by the U.S. Food and Drug Administration for the anticholesteremic agent, lovastin in November 1987. Prevention of coronary heart disease with cholestyramine-induced anticholesteremic agent; Information on the Cholesterol Lowering Atherosclerosis...

  • "Satin" drugs, mortality, and stroke prevention. Stiffman, Michael N. // Journal of Family Practice;Oct97, Vol. 45 Issue 4, p293 

    The article discusses research being done on the effectiveness of statin drugs in preventing death, coronary heart disease and stroke. It references a study by P. R. Hebert, J. M. Gaziano, K. S. Chanand C. H. Hennekens published in the "Journal of American Medical Association." The study found a...

  • Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Rotella, Carlo M.; Zaninelli, Augusto; Le Grazie, Cristina; Hanson, Mary E.; Gensini, Gian Franco // Lipids in Health & Disease;2010, Vol. 9, p80 

    Background: Treatment guidelines recommend LDL-C as the primary target of therapy in patients with hypercholesterolemia. Moreover, combination therapies with lipid-lowering drugs that have different mechanisms of action are recommended when it is not possible to attain LDL-C targets with statin...

  • NZ, British, Australian statin guidelines best bet.  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p1 

    The article discusses research being done on the effectiveness and efficiency of different guidelines on statin treatment for preventing mortality from coronary heart disease (CHD). It references a study by D. G. Manuel and colleagues in the June 1, 2006 online issue of the "British Medical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics